taken following decisions: 1.Considered, approved and took on record the unaudited Financial Results of the company for the quarter ended and half year ended on 30th September 2025 along ....
Awaiting price reaction for this filing.
Soni Medicare's Board approved unaudited results for Q2 and H1 FY26 on 14 November 2025. Revenue from operations fell to Rs. 623.46 lakhs in Q2 FY26 from Rs. 836.37 lakhs in Q2 FY25, a drop of about 25%. Half-year revenue also dipped to Rs. 1,351.17 lakhs from Rs. 1,544.64 lakhs. The company swung deeper into the red with a net loss of Rs. 121.05 lakhs for H1 FY26 versus a Rs. 40.03 lakh loss a year ago; Q2 standalone loss was Rs. 91.95 lakhs versus a Rs. 46.60 lakh profit last year. Other equity has worsened to negative Rs. 417.70 lakhs, and operating cash flow was negative at Rs. (22.75) lakhs. Borrowings (current) more than doubled to Rs. 261.30 lakhs while cash balance fell to Rs. 147.94 lakhs. The auditor (Tambi Ashok & Associates) issued an unqualified limited review report with no qualifications.
Weak set of numbers – shrinking revenue, widening losses, negative net worth and negative operating cash flow point to serious financial stress for shareholders. Short-term stock sentiment is likely negative, though the small size and limited liquidity of the scrip may keep the impact muted.